Kyverna Therapeutics IncKYTX
Price$6.52

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$152.6MTTM through 30 Jun 2026
Free Cash Flow -$159MTTM through 30 Jun 2026

Margins

Current

Returns

-92.2%ROE
-69.4%ROA

Balance Sheet Health

Debt / Equity0.15x
Current Ratio9.06x
Net Debt-$6.9Mnet cash position
Cash & Equivalents$31.8M

Quality Metrics

Altman Z-Score0.55
Piotroski F-Score1 / 9
Earnings-Beat Rate100.0%

Multi-Year Trend

Diluted EPS-$2.92TTM
'23'24'25
FY2025: $-3.64

Dividend

No dividend

Capital Allocation

R&D Spend$115.3M

Segment Performance

SegmentRevenueYoYOutlook
Cell Therapies for Autoimmune Diseases$0
View details

Rolling BLA submission for SPS initiated in May 2026 with commercial launch targeted for 2027.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.